title: Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.
abstract: Rubinstein-Taybi syndrome (RSTS) is a complex autosomal-dominant disease characterized by mental and growth retardation and skeletal abnormalities. A majority of the individuals diagnosed with RSTS carry heterozygous mutation in the gene CREBBP, but a small percentage of cases are caused by mutations in EP300. To investigate the contribution of p300 to RSTS pathoetiology, we carried out a comprehensive and multidisciplinary characterization of p300(+/-) mice. These mice exhibited facial abnormalities and impaired growth, two traits associated to RSTS in humans. We also observed abnormal gait, reduced swimming speed, enhanced anxiety in the elevated plus maze, and mild cognitive impairment during the transfer task in the water maze. These analyses demonstrate that p300(+/-) mice exhibit phenotypes that are reminiscent of neurological traits observed in RSTS patients, but their comparison with previous studies on CBP deficient strains also indicates that, in agreement with the most recent findings in human patients, the activity of p300 in cognition is likely less relevant or more susceptible to compensation than the activity of CBP.
authors.affiliation: Instituto de Neurociencias de Alicante (Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas), Campus de Sant Joan, Apt. 18, Sant Joan d'Alacant, 03550 Alicante, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: Viosca
authors.forename: Jose P
authors.initials: JP
authors.lastname: Lopez-Atalaya
authors.forename: Roman
authors.initials: R
authors.lastname: Olivares
authors.forename: Richard
authors.initials: R
authors.lastname: Eckner
authors.forename: Angel
authors.initials: A
authors.lastname: Barco
mesh_terms: D000107:Acetylation; D000818:Animals; D001007:Anxiety / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D050882:CREB-Binding Protein / Q000235:genetics / Q000378:metabolism*; D002843:Chromatin / Q000378:metabolism; D003071:Cognition; D003072:Cognition Disorders / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D020820:Dyskinesias / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D050881:E1A-Associated p300 Protein / Q000235:genetics / Q000378:metabolism*; D005145:Face / Q000002:abnormalities / Q000473:pathology; D006624:Hippocampus / Q000473:pathology / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009460:Neurologic Examination; D009483:Neuropsychological Tests; D010641:Phenotype; D012415:Rubinstein-Taybi Syndrome / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D013577:Syndrome
chemical_list: D002843:Chromatin; D050882:CREB-Binding Protein; C494364:Crebbp protein, mouse; D050881:E1A-Associated p300 Protein; C494361:Ep300 protein, mouse